Enzymatica conducts several enzyme-based early development projects in order to strengthen its product portfolio in the long term. In close collaboration with clinical researchers, Enzymatica develops medical devices primarily in the therapeutic area of colds.

Enzymatica focuses on product development based on the established and patented barrier technology on which the ColdZyme cold product is based. The product development focus is on broadening the range of ColdZyme products and developing new applications or indications based on the ColdZyme formulation.

Barrier technology

The barrier in ColdZyme consists of a transparent liquid solution comprising a hypertonic substance and enzyme. The main mechanism of action of the barrier is based on the generation of a viscous osmotic solution (barrier or film) on the mucous membrane in the mouth/throat which attracts fluid from the throat mucous membrane surface. This fluid includes viruses. When applied in the oral cavity/oropharynx, as in the case of ColdZyme, the total viral load in the oropharynx is reduced, thus facilitating a faster natural recovery from a common cold.

Enzyme from deep-sea fish

A key subcomponent of the effective barrier is an enzyme from deep-sea cod. The enzyme is a natural protein that serves as a catalyzer, in other words, it can increase the speed of chemical reactions. The enzyme from deep-sea cod is a cold-adapted trypsin, which has evolved and adapted to activity at around four degrees Celsius. This adaptation to the cold has made this type of enzyme more effective when it comes into contact with the body temperature of humans and catalytic activity is several times higher than that of the corresponding human enzyme. High specific activity and low substrate affinity at low and moderate temperatures combined with an attractive stability profile make the enzyme well suited for application in medical devices.


Source: Asgeirsson et al, European Journal of Biochemistry, vol. 180, no. 1,


In the longer term, our focus is on developing products for areas of indication that will require further development or optimization of the barrier technology. For example, Enzymatica has a partnership with the Faculty of Odontology in Malmö on a research project involving oral health that is funded by the Knowledge Foundation. The subsidiary Zymetech has a Eurostar-funded partnership with the Danish Technological Institute and the company BioModics in Denmark for development of a product for advanced wound care.